Gout Therapeutics Market Analysis By Drug Class (Nonsteroidal Anti-inflammatory Drugs [NSAIDs], Corticosteroids, Colchicine, Urate-Lowering Agents), By Disease Condition (Acute Gout, Chronic Gout), And Segment Forecasts, 2018 - 2025

Report ID: GVR-1-68038-717-9
Number of Pages: 100
Format: Electronic (PDF)

Historical Range: 2014 - 2015
Industry:Healthcare

Market Segmentation

Gout Therapeutics Drug Class Outlook (Revenue, USD Million,2014 - 2025)
- NSAIDs
- Corticosteroids
- Colchicine
- Urate-Lowering Agents
Gout Therapeutics Application Outlook (Revenue, USD Million,2014 - 2025)
- Acute Gout
- Chronic Gout
Gout Therapeutics Regional Outlook (Revenue, USD Million,2014 - 2025)
- North America
  - The U.S.
    - U.S. Drug Class Outlook (Revenue, USD Million, 2014 - 2025)
      - NSAIDs
      - Corticosteroids
      - Colchicine
      - Urate-Lowering Agents
    - U.S. Disease Condition Outlook (Revenue, USD Million, 2014 - 2025)
      - Acute Gout
      - Chronic Gout
  - Canada
    - Canada Drug Class Outlook (Revenue, USD Million, 2014 - 2025)
      - NSAIDs
      - Corticosteroids
      - Colchicine
      - Urate-Lowering Agents
    - Canada Disease Condition Outlook (Revenue, USD Million, 2014 - 2025)
      - Acute Gout
      - Chronic Gout
- Europe
  - UK
    - UK Drug Class Outlook (Revenue, USD Million, 2014 - 2025)
      - NSAIDs
      - Corticosteroids
      - Colchicine
      - Urate-Lowering Agents
    - UK Disease Condition Outlook (Revenue, USD Million, 2014 - 2025)
      - Acute Gout
      - Chronic Gout
  - Germany
    - Germany Drug Class Outlook (Revenue, USD Million, 2014 - 2025)
      - NSAIDs
      - Corticosteroids
      - Colchicine
      - Urate-Lowering Agents
    - Germany Disease Condition Outlook (Revenue, USD Million, 2014 - 2025)
      - Acute Gout
      - Chronic Gout
- Asia Pacific
  - Japan
    - Japan Drug Class Outlook (Revenue, USD Million, 2014 - 2025)
      - NSAIDs
      - Corticosteroids
      - Colchicine
      - Urate-Lowering Agents
    - Japan Disease Condition Outlook (Revenue, USD Million, 2014 - 2025)
      - Acute Gout
      - Chronic Gout
  - China
    - China Drug Class Outlook (Revenue, USD Million, 2014 - 2025)
      - NSAIDs
      - Corticosteroids
      - Colchicine
      - Urate-Lowering Agents
    - China Disease Condition Outlook (Revenue, USD Million, 2014 - 2025)
      - Acute Gout
      - Chronic Gout
- Latin America
  - Brazil
    - Brazil Drug Class Outlook (Revenue, USD Million, 2014 - 2025)
      - NSAIDs
      - Corticosteroids
      - Colchicine
      - Urate-Lowering Agents
    - Brazil Disease Condition Outlook (Revenue, USD Million, 2014 - 2025)
      - Acute Gout
      - Chronic Gout
  - Mexico
    - Mexico Drug Class Outlook (Revenue, USD Million, 2014 - 2025)
      - NSAIDs
      - Corticosteroids
      - Colchicine
      - Urate-Lowering Agents
    - Mexico Disease Condition Outlook (Revenue, USD Million, 2014 - 2025)
      - Acute Gout
      - Chronic Gout
- MEA
  - South Africa
    - South Africa Drug Class Outlook (Revenue, USD Million, 2014 - 2025)
      - NSAIDs
      - Corticosteroids
      - Colchicine
      - Urate-Lowering Agents
    - South Africa Disease Condition Outlook (Revenue, USD Million, 2014 - 2025)
      - Acute Gout
      - Chronic Gout

Report content

Qualitative Analysis

Industry overview
Industry trends
Market drivers and restraints
乐鱼体育手机网站入口
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments

Quantitative Analysis

Market size, estimates, and forecast from 2014 to 2025
产品细分市场估计和预测up to 2025
Regional market size and forecast for product segments up to 2025
Market estimates and forecast for application segments up to 2025
Regional market size and forecast for application segments up to 2025
Company financial performance

GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

NEED A CUSTOM REPORT?

We can customize every report -free of charge- including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

ESOMAR certified & member

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read ourprivacy policy.